London South East | The UK's favourite investor portal.

RNS Number : 3554R
Angle PLC
28 February 2019
For immediate release
28 February 2019

ANGLE plc ("the Company")

FIRST SUBJECTS ENROLLED IN OVARIAN CANCER CLINICAL VERIFICATION STUDY

Study to confirm the combination of ANGLE's Parsortix system with its new HyCEAD Ziplex platform as sample-to-answer for accurate pelvic mass triage

Study expected to complete in Q1 CY2020

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that ethics approval has been obtained from the University of Rochester Medical Center Wilmot Cancer Institute for its ovarian cancer clinical verification study ("the Study").

The first subjects have already been enrolled into the Study, which comprises a 70-subject pre-study followed by a 200-subject clinical study, evaluating the use of ANGLE's modified and further optimised ParsortixTM and HyCEADTM ZiplexÂ® platforms as a simple blood test to detect the presence of ovarian cancer in women with a pelvic mass. The Study is expected to complete in Q1 CY2020.

Since its acquisition of the HyCEAD Ziplex downstream analysis platform in November 2017, ANGLE has undertaken extensive optimisation of both the HyCEAD Ziplex platform and its combination with the Parsortix system to provide an assay predictive of ovarian cancer risk. A detailed market review has been completed to identify key user requirements for adoption of the test and work has been completed to address these identified user requirements with key improvements including:

Â· improved analytical sensitivity of the HyCEAD Ziplex platform enabling the detection of a single cancer cell harvested by the Parsortix system from a 10ml blood sample

Â· incorporation of assay controls and use of fractional sampling to demonstrate reproducibility and reliability of performance

Â· development of methods to allow for patient blood sample processing for up to 96 hours after collection without significantly compromising the assay sensitivity, thus opening up the possibility for the test to be offered by large central laboratories with sufficient time for sample transportation.

The entire sample-to-answer process has been analytically validated using contrived samples and is now being tested in the clinical setting. Testing of the modified and further optimised Parsortix and HyCEAD Ziplex platforms has begun in the pre-study using known ovarian cancer patients and healthy volunteers to confirm the performance of various improvements to the process. Upon successful completion of the initial testing phase, the blinded, independently controlled 200-subject verification study of the targeted population of pelvic mass patients prior to surgery will begin. The Study has been designed to evaluate performance of the predictive assay in a new patient cohort and, assuming the initial testing is successful, is expected to complete within 12 months.

Once the new performance data is available and, assuming comparable res

Mon, 25th Feb 2019 07:00
RNS Number : 9337Q
Angle PLC
25 February 2019
For immediate release
25 February 2019
ANGLE plc ("the Company")

LEADING CUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX RESULTING IN A 30-FOLD INCREASE IN HARVESTED CANCER CELLS FOR ANALYSIS

Viable cancer cells harvested from diagnostic leukapheresis (DLA) samples for key downstream processes such as in vitro culture

Success achieved with cryopreserved DLA product demonstrates long term stability for Parsortix system separation

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that one of its leading customers, the Disseminated Cancer Cell Network (DCCNet), Duesseldorf, an interdisciplinary team of researchers and clinicians whose goal is to better understand systemic disease in cancer and to improve individualised therapy in cancer patients, has published new results in a peer-reviewed journal of work done to harvest circulating tumor cells (CTCs) from diagnostic leukapheresis (DLA) samples.

Leukapheresis is a standard procedure routinely used in the clinic to enrich mononuclear cells (certain types of white blood cells (WBCs)) from blood for various applications, including stem cell harvest, with the remainder of the blood returned to the circulation. The DCCNet had previously published that during DLA, several litres of patient blood can be processed resulting in a DLA product of typically just 40ml containing primarily WBCs but also CTCs. They demonstrated that DLA results in more patients with CTCs harvested and an increase of the median CTC numbers by 30-fold compared to analysis of blood samples. The method has been validated by the DCCNet and a European multi-centre study (CTCTrap) in metastatic prostate and breast cancer patients, demonstrating that the workflow yields significantly higher CTC numbers and that the procedure could be safely performed in different clinical environments.

New research on this topic has now been published by the DCCNet at the University Hospital and Medical Faculty of the Heinrich-Heine University of Duesseldorf as a peer-reviewed publication in the journal Clinical Chemistry and is available at https://angleplc.com/library/publications/.

The researchers found that the ParsortixTM system is highly effective in reducing the WBC background from DLA products without interfering with the viability of captured CTCs. This is a major prerequisite to allow successful processing of the DLA product in future clinical situations with low CTC numbers and to enable CTC culturing. Without Parsortix enrichment, WBCs rapidly outgrew the CTC cultures. The increased number of viable CTCs and the enhanced sample purity improved the ability to culture the CTCs. Culturing CTCs is a challenging task and this approach opens the potential for chemo-sensitivity testing in-vitro on isolated and cultured CTCs to determine which drugs may benefit the patient.

The researchers also demonstrated tha

Latest Share Chat

Member Info for Morgank

Followers

Following

Posts (Last 30 Days)

Posts (All Time)

Last Post

Member Since

Share Chat Post Distribution (Last 30 Days)

Activity Log (Last 30 Days)